文献速递类风湿关节炎

两项早期类风湿关节炎队列达标治疗策略下的缓解比较

Achievement of remission in two early rheumatoid arthritis cohorts implementing different treat-to-target strategies.
PubMed 文献 · Arthritis Rheumatol · 2020-02-23

该研究比较了挪威ARCTIC随机对照试验与NOR-VEAC观察性研究两个早期类风湿关节炎达标治疗队列的缓解情况。ARCTIC以DAS44<1.6且44个肿胀关节计数为0为目标,NOR-VEAC以DAS28<2.6为目标。两队列多数患者达到各自目标,但ARCTIC患者随访期间达到ACR/EULAR布尔缓解的几率更高。

要点

  • 两队列中超过半数患者6个月达到各自研究设定的治疗目标。
  • ARCTIC患者在3、12、24个月达到ACR/EULAR布尔缓解的几率均高于NOR-VEAC。
  • 采用更严格的缓解定义作为靶目标可能带来更有利的达标治疗结局。

核心结论

  • 在两项早期RA达标治疗队列中,多数患者达到研究设定的治疗目标,且以更严格缓解定义为目标的ARCTIC队列达到ACR/EULAR布尔缓解的几率更高。

研究设计与样本

  • 研究分析ARCTIC随机对照策略试验与NOR-VEAC观察性研究两个挪威多中心队列,纳入未使用过DMARD的RA患者并实施达标治疗,随访两年。

主要发现

  • ARCTIC纳入189例、NOR-VEAC纳入330例患者;两队列各超过半数患者在6个月达到研究特定目标,12和24个月增至超过60%。
  • ARCTIC较NOR-VEAC达到ACR/EULAR布尔缓解的比值比在3个月为1.73(95%CI 1.03-2.89),12个月为1.97(95%CI 1.21-3.20),24个月为1.82(95%CI 1.05-3.16)。

关键数值与推荐

  • ARCTIC目标为DAS44<1.6且44个肿胀关节计数为0,NOR-VEAC目标为较宽松的DAS28<2.6。

临床怎么用

  • 对早期RA实施达标治疗时,设定更严格的缓解目标(如DAS44<1.6且肿胀关节计数为0)可能提高达到ACR/EULAR布尔缓解的机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare achievement of remission in two early rheumatoid arthritis (RA) treat-to-target (TTT) cohorts, one tight control cohort targeting stringent remission in a randomized controlled strategy trial and one observational cohort targeting a looser definition of remission in clinical practice. METHODS: We analyzed data from the ARCTIC trial and the NOR-VEAC observational study. Both were Norwegian multicenter studies including disease modifying anti-rheumatic drug (DMARD)-naïve RA-patients and implementing TTT. The target in ARCTIC was remission defined as a Disease Activity Score (DAS44) <1.6 plus 0 of 44 swollen joint count, while the target in NOR-VEAC was the less stringent remission of DAS28<2.6. We assessed achievement of the study-specific targets and compared achievement of the ACR/ EULAR Boolean remission during two years of follow-up. RESULTS: We included 189 patients from ARCTIC and 330 patients from NOR-VEAC. More than half in each cohort had reached the study-specific target at 6 months, increasing to more than 60% at 12 and 24 months. The odds of reaching ACR/EULAR Boolean remission during follow-up were higher in ARCTIC than in NOR-VEAC, with statistically significant differences at 3 months (OR 1.73; 95% CI 1.03-2.89), 12 months (OR 1.97; 95% CI 1.21-3.20) and 24 months (OR 1.82; 95% CI 1.05 - 3.16). CONCLUSION: A majority of patients in both cohorts reached the study-specific treatment targets. More patients in ARCTIC than in NOR-VEAC achieved ACR/EULAR Boolean remission during follow-up, suggesting that targeting a more stringent definition of remission provide further potential for favorable outcomes of a TTT strategy.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Norvang V, Brinkmann GH, Yoshida K, et al. Achievement of remission in two early rheumatoid arthritis cohorts implementing different treat-to-target strategies. Arthritis Rheumatol. 2020. PMID: 32090491. doi:10.1002/art.41232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。